Medpage -- The relative risk of vertebral fracture was reduced by 45% by the use of the selective tissue estrogenic activity regulator tibolone, an investigational agent to ease menopause symptoms or prevent osteoporosis, researchers here said. Tibolone also reduced the risk of non-vertebral fracture and invasive breast cancer in a randomized, double-blind, placebo-controlled study, according to Steven Cummings, M.D., of the California Pacific Medical Center, and colleagues.
